Neuroregenerative Effects of Simvastatin in TBI
Neuroregenerative Effects of Simvastatin in TBI
批准号:
9162263
负责人:
NEELIMA CHAUHAN
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-01-01 至 2016-12-31
关键词:
AcuteAddressAfghanistanAftercareAnatomyAnti-Inflammatory AgentsAnti-inflammatoryApoptosisAppearanceAxonBiochemicalBrain ConcussionBrain InjuriesBrain-Derived Neurotrophic FactorCaringCholesterolChronicCoenzyme ACognitionCognitive deficitsComplexDendritesEpidemicEtiologyEventExposure toFunctional disorderGrowthHeterogeneityHippocampus (Brain)InjuryInvestigationIraqLearningLifeMemoryModelingMolecularMono-SMultiple TraumaNatureNerve DegenerationNerve RegenerationNeuronsNeuroprotective AgentsNeurotransmittersOrthopedicsOutcomeOxidoreductasePatientsPhysiologicalPost-Traumatic Stress DisordersPropertyProviderRattusReportingResearch PriorityServicesSeveritiesSignal PathwaySimvastatinSleeplessnessSoldierStagingSymptomsSynapsesTestingTherapeuticTimeTraumatic Brain InjuryTreatment EfficacyUncertaintyUp-RegulationVeteransWarangiogenesisastrogliosisaxon injurybehavioral outcomecare seekingcognitive disabilitycombatcontrolled cortical impactdisabilitydrug candidatefunctional outcomeshigh riskimprovedinhibitor/antagonistinstrumentinterestmembermouse modelneurogenesisneuroinflammationneurotrophic factoropen woundpleiotropismscreeningtargeted treatmenttherapeutic targettreatment effect
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant):
Traumatic brain injury (TBI) has emerged as a Signature injury among U.S. forces serving in Afghanistan and Iraq wars. In the combat situation, treatment for Veterans sustaining TBI is often delayed due to several reasons including instant un-/mis-identification, appearance of symptoms days/weeks/months after injury, and hence soldiers sustaining TBI are highly likely to be returned to the battlefield before subtle TBI problems are resolved. A Veteran's first interaction with the VA provider may occur months or even years after actual TBI event, and significant number of these Veterans might not seek care from VA until several months or even years after their return from the combat and their transition to Veteran status. Furthermore, some of the symptoms of TBI, such as irritability and insomnia, may overlap with other conditions, such as post-traumatic stress disorder (PTSD), and hence may be mis-treated. Therefore, considerable cases of TBI may go "undiagnosed" and "untreated" until much later after actual injury that adds to the growing heterogeneity of TBI injury per se. Current therapeutic strategies do help TBI patients to regain some degree of function, but there remains a compelling need for investigating therapeutic efficacy of candidate drugs as a "late stage" treatment after TBI, that most Veterans are currently facing. Given the multifactorial heterogeneous nature of TBI spanning over an extended period of time from days-months-years, and given the increasing number of returning war Veterans already sustaining TBI but facing "undiagnosed" and "untreated" status, pre-disposed to long term TBI heterogeneity, calls for a treatment aimed at multiple therapeutic targets rather than mono- treatment. In that regard, known pleiotropy of Simvastatin including its neurotrophic, neuroregenerative, synaptotrophic and anti-inflammatory properties, independent of its cholesterol-lowering properties, are remarkable. With particular reference to Simvastatin, studies reported this far have shown immediate treatment effects of Simvastatin after TBI, and did not address current need for "late treatment of TBI Veterans. This project will test the hypothesis that Post-acute treatment with Simvastatin will effectively restore neuronal and synaptic integrity and improve functional outcome in the CCI mouse model of TBI by analyzing neuro-axonal- dendritic re-growth and connectivity, expression of neurotrophic factors critically involved in neuroregeneration, synaptic
neurotransmitter markers critically involved in learning and memory, and by evaluating functional outcome after Simvastatin treatment at a more chronic stage after TBI.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
Experimental induction of type 2 diabetes in aging-accelerated mice triggered Alzheimer-like pathology and memory deficits.
衰老加速小鼠中2型糖尿病的实验诱导触发了阿尔茨海默氏症样病理和记忆缺陷。
DOI:
10.3233/jad-131238
发表时间:
2014
期刊:
Journal of Alzheimer's disease : JAD
影响因子:
--
作者:
[Mehla J, Chauhan BC, Chauhan NB]
通讯作者:
Chauhan NB
DOI:
10.46439/neuroscience.1.004
发表时间:
2020
期刊:
The neuroscience chronicles
影响因子:
--
作者:
[Chauhan, Neelima B]
通讯作者:
Chauhan, Neelima B
Therapeutic Efficacy of Intranasal WGA-GLP1 in AD
-
批准号:8512104
-
项目类别:
-
资助金额:$23.93万
-
财政年份:2013
-
负责人:NEELIMA CHAUHAN
-
依托单位:
Therapeutic Efficacy of Intranasal WGA-GLP1 in AD
-
批准号:8640998
-
项目类别:
-
资助金额:$19.74万
-
财政年份:2013
-
负责人:NEELIMA CHAUHAN
-
依托单位:
Neuroregenerative Effects of Simvastatin in TBI
-
批准号:8974190
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2013
-
负责人:NEELIMA CHAUHAN
-
依托单位:
WGA as a Novel Vehicle for Intranasal Delivery of an Anti-A-beta Antibody in AD
-
批准号:8091181
-
项目类别:
-
资助金额:$16.07万
-
财政年份:2011
-
负责人:NEELIMA CHAUHAN
-
依托单位:
WGA as a Novel Vehicle for Intranasal Delivery of an Anti-A-beta Antibody in AD
-
批准号:8432312
-
项目类别:
-
资助金额:$7.8万
-
财政年份:2011
-
负责人:NEELIMA CHAUHAN
-
依托单位:
WGA as a Novel Vehicle for Intranasal Delivery of an Anti-A-beta Antibody in AD
-
批准号:8246405
-
项目类别:
-
资助金额:$13.39万
-
财政年份:2011
-
负责人:NEELIMA CHAUHAN
-
依托单位:
Reduction of Amyloid Burden by Antisense APP
-
批准号:6780661
-
项目类别:
-
资助金额:$14.81万
-
财政年份:2004
-
负责人:NEELIMA CHAUHAN
-
依托单位:
Determining Therapeutic Efficacy of AGE in AD
-
批准号:6702792
-
项目类别:
-
资助金额:$19.48万
-
财政年份:2004
-
负责人:NEELIMA CHAUHAN
-
依托单位:
Reduction of Amyloid Burden by Antisense APP
-
批准号:6864811
-
项目类别:
-
资助金额:$14.81万
-
财政年份:2004
-
负责人:NEELIMA CHAUHAN
-
依托单位:
Determining Therapeutic Efficacy of AGE in AD
-
批准号:6848349
-
项目类别:
-
资助金额:$19.48万
-
财政年份:2004
-
负责人:NEELIMA CHAUHAN
-
依托单位:
海外基金